Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) registered a 8.10% increase, still its new closing price is 182.80% up from the company’s 1 year high of 6.97.It posted 27.85% gains in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 3 buy or better ratings. The 6 stock analysts following this company have an average price target at $11.50, with individual PT in the $6.50-$18.00 range. The shares moved at $7.07, implying that brokerage firms see shares gaining about 87.53% in twelve months time.

Synergy Pharmaceuticals Inc. (SGYP) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 16.09% rise year to date. A 10% Owner at Synergy Pharmaceuticals Inc. (SGYP) offloaded shares in a transaction closed on Friday November 04, 2016. PAULSON & CO. INC. sold 140,000 shares in the company at $4.24 each and collected $593,001 in proceeds. PAULSON & CO. INC. now owns 24,088,655 shares in the company after this transaction. A 10% Owner in the company, PAULSON & CO. INC., disclosed a transaction on Wednesday September 28, 2016 that ended up generating $308,001 from the sale of 54,300 shares at $5.69 per share.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Upcoming Results on Tap

Synergy Pharmaceuticals Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.14 in that period. Sales during the quarter are predicted to arrive at $0.

Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.22. The mean forecast was for $0 and $-0.20 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.23/share.

Synergy Pharmaceuticals Inc. (SGYP) Brokerage Update 

Synergy Pharmaceuticals Inc. (SGYP) is in Citigroup’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Buy by Citigroup, according to news reported on Friday December 18, 2015. Over the last six months and over the last three months, the shares of Synergy Pharmaceuticals Inc. (SGYP), have changed 71.19% and 48.53%, respectively.